Document and Entity Information |
9 Months Ended |
|---|---|
Sep. 30, 2016 | |
| Document Information [Line Items] | |
| Document Type | 6-K |
| Amendment Flag | false |
| Document Period End Date | Sep. 30, 2016 |
| Document Fiscal Year Focus | 2016 |
| Document Fiscal Period Focus | Q3 |
| Trading Symbol | ICLR |
| Entity Registrant Name | ICON PLC |
| Entity Central Index Key | 0001060955 |
| Current Fiscal Year End Date | --12-31 |
| X | ||||||||||
- Definition If the value is true, then the document is an amendment to previously-filed/accepted document. No definition available.
|
| X | ||||||||||
- Definition End date of current fiscal year in the format --MM-DD. No definition available.
|
| X | ||||||||||
- Definition This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY. No definition available.
|
| X | ||||||||||
- Definition This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD. No definition available.
|
| X | ||||||||||
- Definition The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other". No definition available.
|
| X | ||||||||||
- Definition A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Trading symbol of an instrument as listed on an exchange. No definition available.
|
| X | ||||||||||
- Definition Noncurrent capital government grants, which are amortized and recognized in earnings over the grant period. No definition available.
|
| X | ||||||||||
- Definition Capital Redemption Reserve No definition available.
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after allocation of valuation allowances of noncurrent deferred tax asset attributable to deductible temporary differences and carryforwards. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, netted by jurisdiction and classified as noncurrent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Condensed Consolidated Balance Sheets (Parenthetical) - € / shares |
Sep. 30, 2016 |
Dec. 31, 2015 |
[1] | ||
|---|---|---|---|---|---|
| Ordinary shares, par value | € 0.06 | € 0.06 | |||
| Ordinary shares, shares authorized | 100,000,000 | 100,000,000 | |||
| Ordinary shares, shares issued | 55,827,713 | 54,958,912 | |||
| Ordinary shares, shares outstanding | 55,827,713 | 54,958,912 | |||
| |||||
| X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The maximum number of common shares permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Condensed Consolidated Statements of Operations - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
|
| Revenue: | ||||
| Gross revenue | $ 622,261 | $ 557,095 | $ 1,754,491 | $ 1,584,559 |
| Reimbursable expenses | (202,060) | (162,354) | (523,138) | (412,930) |
| Net revenue | 420,201 | 394,741 | 1,231,353 | 1,171,629 |
| Costs and expenses: | ||||
| Direct costs | 243,244 | 226,555 | 709,831 | 679,593 |
| Selling, general and administrative expense | 81,235 | 82,435 | 242,192 | 243,310 |
| Depreciation and amortization | 14,543 | 14,366 | 44,120 | 42,535 |
| Restructuring | 4,065 | 8,159 | ||
| Total costs and expenses | 343,087 | 323,356 | 1,004,302 | 965,438 |
| Income from operations | 77,114 | 71,385 | 227,051 | 206,191 |
| Interest income | 462 | 531 | 1,155 | 1,026 |
| Interest expense | (3,227) | (1,178) | (9,640) | (1,686) |
| Income before provision for income taxes | 74,349 | 70,738 | 218,566 | 205,531 |
| Provision for income taxes | (10,470) | (9,196) | (30,649) | (29,534) |
| Net income | $ 63,879 | $ 61,542 | $ 187,917 | $ 175,997 |
| Net income per Ordinary Share: | ||||
| Basic | $ 1.15 | $ 1.05 | $ 3.39 | $ 2.95 |
| Diluted | $ 1.13 | $ 1.02 | $ 3.33 | $ 2.85 |
| Weighted average number of Ordinary Shares outstanding: | ||||
| Basic | 55,734,773 | 58,659,782 | 55,355,020 | 59,728,608 |
| Diluted | 56,645,239 | 60,369,898 | 56,475,319 | 61,785,849 |
| X | ||||||||||
- Definition Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Cost associated with reimbursable income. This occurs when a services entity incurs expenses on behalf of the client and passes through the cost of reimbursable expenses to a client. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense for debt. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands |
9 Months Ended | ||||
|---|---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
||||
| Cash flows from operating activities: | |||||
| Net income | $ 187,917 | $ 175,997 | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||
| Loss on disposal of property, plant and equipment | 27 | 7 | |||
| Depreciation expense | 31,374 | 30,037 | |||
| Amortization of intangibles | 12,746 | 12,498 | |||
| Amortization of grants | (33) | (29) | |||
| Accrued interest on short term investments | (498) | ||||
| Realised gain on sale of short term investments | (39) | ||||
| Share compensation expense | 31,135 | 24,043 | |||
| Amortization of gain on interest rate hedge | (693) | ||||
| Amortization of financing costs | 422 | ||||
| Deferred taxes | 3,262 | (749) | |||
| Changes in assets and liabilities: | |||||
| Decrease/(increase) in accounts receivable | 17,825 | (7,817) | |||
| Increase in unbilled revenue | (18,373) | (50,707) | |||
| Increase in other receivables | (11,876) | (10,701) | |||
| Increase in prepayments and other current assets | (1,395) | (11,718) | |||
| (Increase)/decrease in other non-current assets | (1,857) | 272 | |||
| (Decrease)/increase in payments on account | (67,868) | 10,615 | |||
| Decrease in other current liabilities | (48,200) | (20,363) | |||
| Increase in other non-current liabilities | 4,118 | 1,843 | |||
| Increase in income taxes payable | 4,163 | 9,097 | |||
| (Decrease)/increase in accounts payable | (2,826) | 1,102 | |||
| Change in deferred tax liability | (3,666) | ||||
| Net cash provided by operating activities | 135,665 | 163,427 | |||
| Cash flows from investing activities: | |||||
| Purchase of property, plant and equipment | (29,345) | (36,255) | |||
| Purchase of subsidiary undertakings | (54,009) | (102,756) | |||
| Cash acquired with subsidiary undertaking | 1,842 | ||||
| Purchase of short term investments | (19,047) | (9,652) | |||
| Sale of short term investments | 21,484 | 25,170 | |||
| Net cash used in investing activities | (79,075) | (123,493) | |||
| Cash flows from financing activities: | |||||
| Proceeds from exercise of share options & restricted share units | 7,243 | 18,375 | |||
| Share issuance costs | (16) | (6) | |||
| Tax benefit from the exercise of share options | 5,381 | 3,014 | |||
| Repurchase of ordinary shares | (286,923) | ||||
| Share repurchase costs | (802) | ||||
| Drawdown of bank credit lines and loan facilities | 73,000 | 350,000 | |||
| Repayment of bank credit lines and loan facilities | (20,000) | ||||
| Financing costs | (6,626) | ||||
| Net cash provided by financing activities | 58,982 | 83,658 | |||
| Effect of exchange rate movements on cash | (175) | (7,244) | |||
| Net increase in cash and cash equivalents | 115,397 | 116,348 | |||
| Cash and cash equivalents at beginning of period | 103,911 | [1] | 118,900 | ||
| Cash and cash equivalents at end of period | $ 219,308 | $ 235,248 | |||
| |||||
| X | ||||||||||
- Definition Accrued Interest On Short Term Bank Deposits No definition available.
|
| X | ||||||||||
- Definition Amortization Of Gain On Interest Rate Hedge No definition available.
|
| X | ||||||||||
- Definition Payments for Share Repurchase Costs No definition available.
|
| X | ||||||||||
- Definition Proceeds From Stock Options And Restricted Shares Exercised No definition available.
|
| X | ||||||||||
- Definition Amortization of Government Grants. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of deferred income tax expense (benefit) and income tax credits. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Change during the period in carrying value for all deferred liabilities due within one year or operating cycle. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The increase (decrease) during the reporting period in other current operating liabilities not separately disclosed in the statement of cash flows. No definition available.
|
| X | ||||||||||
- Definition The increase (decrease) during the reporting period in other noncurrent operating assets not separately disclosed in the statement of cash flows. No definition available.
|
| X | ||||||||||
- Definition The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows. No definition available.
|
| X | ||||||||||
- Definition The increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow to reacquire common stock during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow for loan and debt issuance costs. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow for cost incurred directly with the issuance of an equity security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Condensed Consolidated Statements of Shareholders' Equity and Comprehensive Income - 9 months ended Sep. 30, 2016 - USD ($) $ in Thousands |
Total |
Ordinary Shares |
Additional Paid-in Capital |
Capital Redemption Reserve |
Accumulated Other Comprehensive Income |
Retained Earnings |
|||
|---|---|---|---|---|---|---|---|---|---|
| Balance (in shares) at Dec. 31, 2015 | 54,958,912 | [1] | 54,958,912 | ||||||
| Balance at Dec. 31, 2015 | $ 763,096 | [1] | $ 4,679 | $ 383,395 | $ 715 | $ (61,636) | $ 435,943 | ||
| Comprehensive Income: | |||||||||
| Net income | 187,917 | 187,917 | |||||||
| Currency translation adjustment | (3,664) | (3,664) | |||||||
| Currency impact of long term funding | 750 | 750 | |||||||
| Tax on currency impact of long term funding | 389 | 389 | |||||||
| Unrealized capital gain - investments | 322 | 322 | |||||||
| Amortization of interest rate hedge | (693) | (693) | |||||||
| Total comprehensive income | 185,021 | (2,896) | 187,917 | ||||||
| Exercise of share options (in shares) | 268,713 | ||||||||
| Exercise of share options | 7,203 | $ 18 | 7,185 | ||||||
| Issue of restricted/performance share units (in shares) | 600,088 | ||||||||
| Issue of restricted/performance share units | 40 | 40 | |||||||
| Share issuance costs | (16) | (16) | |||||||
| Non-cash stock compensation expense | 31,135 | 31,135 | |||||||
| Tax benefit on exercise of options | $ 5,381 | 5,381 | |||||||
| Balance (in shares) at Sep. 30, 2016 | 55,827,713 | 55,827,713 | |||||||
| Balance at Sep. 30, 2016 | $ 991,860 | $ 4,697 | $ 427,120 | $ 715 | $ (64,532) | $ 623,860 | |||
| |||||||||
| X | ||||||||||
- Definition Adjustment that results from the process of translating the impact of long-term funding into the functional currency of the reporting entity. No definition available.
|
| X | ||||||||||
- Definition Tax impact on the adjustment that results from the process of translating the impact of long-term funding into the functional currency of the reporting entity. No definition available.
|
| X | ||||||||||
- Definition This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation". Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of share options (or share units) exercised during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Value of stock issued as a result of the exercise of stock options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Basis of Presentation |
9 Months Ended |
|---|---|
Sep. 30, 2016 | |
| Basis of Presentation |
1. Basis of Presentation
These condensed consolidated financial statements, which have been
prepared in accordance with United States generally accepted
accounting principles (“US GAAP”), have not been
audited. The condensed consolidated financial statements reflect
all adjustments, which are, in the opinion of management, necessary
to present a fair statement of the operating results and financial
position for the periods presented. The preparation of the
condensed consolidated financial statements in conformity with US
GAAP requires management to make estimates and assumptions that
affect reported amounts and disclosures in the condensed
consolidated financial statements. Actual results could differ from
those estimates.
The condensed consolidated financial statements should be read in
conjunction with the accounting policies and notes to the
consolidated financial statements included in ICON’s Form
20-F for the year ended December 31, 2015. Operating results for
the three and nine months ended September 30, 2016 are not
necessarily indicative of the results that may be expected for the
fiscal period ending December 31, 2016.
|
| X | ||||||||||
- Definition The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Goodwill |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill |
2. Goodwill
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for goodwill. No definition available.
|
Business Combinations |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Combinations |
3. Business Combinations
Acquisitions – Clinical Research Management, Inc.
On September 15, 2016 the Company acquired ClinicalRM resulting in
an initial net cash outflow of $52.4 million inclusive of certain
payments made on behalf of ClinicalRM totalling $9.2
million.
ClinicalRM is a full-service CRO specializing in preclinical
through Phase IV support of clinical research and clinical trial
services for biologics, drugs and devices. The organization helps
customers progress their products to market faster with a wide
array of research, regulatory and sponsor services within
the U.S. and around the globe. ClinicalRM provide full
service and functional research solutions to a broad range of US
government agencies. Their extensive expertise extends across basic
and applied research, infectious diseases, vaccines development and
testing and the response to bio-threats. They have worked in
collaboration with government and commercial customers to respond
to the threat of global viral epidemics. Further
consideration of up to $12.0 million is payable if certain
performance milestones are achieved in respect of periods up to
December 31, 2017.
The acquisition of ClinicalRM has been accounted for as a business
combination in accordance with FASB ASC 805
Business Combinations. The Company has made a
provisional assessment of the fair value of assets acquired and
liabilities assumed as at that date. The table following
summarizes the Company’s provisional estimates of the fair
values of the assets acquired and liabilities assumed:
*Goodwill represents the acquisition of an established workforce
with experience in preclinical through Phase IV support of clinical
research and clinical trial services for biologics, drugs and
devices.
**The Company has made an initial estimate of separate intangible
assets acquired of $9.8 million. This assessment is under
review and will be finalized within 12 months of the date of
acquisition.
Acquisitions - PMG
On December 4, 2015 the Company acquired PMG, resulting in an
initial net cash outflow of $63.5 million, including certain
payments made on behalf of PMG totaling $9.9 million. PMG is
an integrated network of 48 clinical research sites in North
Carolina, South Carolina, Tennessee and Illinois. The site
network includes wholly owned facilities and dedicated clinical
research sites. PMG conducts clinical trials in all major
therapeutic areas and has particular expertise in vaccine,
gastroenterology, cardiovascular, neurology and endocrinology
studies. It has a proprietary database of clinical trial
participants. It also has access to in excess of 2
million active patients via electronic medical records through its
partnerships with healthcare institutions and community physical
practices. The acquisition agreement provides for
working capital targets to be achieved by PMG within 90 days of
acquisition. In March 2016, the Company agreed to pay an
additional $1.6 million on completion of this working capital
review. This amount was paid in April 2016.
The acquisition of PMG has been accounted for as a business
combination in accordance with FASB ASC 805
Business Combinations. The Company has made a
provisional assessment of the fair value of assets acquired and
liabilities assumed as at that date. The table following
summarizes the Company’s provisional estimates of the fair
values of the assets acquired and liabilities assumed:
*Goodwill represents the acquisition of an established workforce
with experience in clinical trial consulting and regulatory support
for the development of drugs, medical devices and diagnostics, with
a specific focus on strategy to increase efficiency and
productivity in product development.
**The Company has made an initial estimate of separate intangible
assets acquired, being customer lists and order backlog, of $10.6
million. This assessment is under review and will be
finalized within 12 months of the date of acquisition.
Acquisitions - MediMedia Pharma Solutions
On February 27, 2015 the Company acquired MediMedia Pharma
Solutions for cash consideration of $104.7 million (net of working
capital adjustments of $4 million). In addition to the cash
consideration, certain payments were made on behalf of MediMedia
Pharma Solutions on completion totaling $11.3 million.
Headquartered in Yardley, Pennsylvania, MediMedia Pharma Solutions
includes MediMedia Managed Markets and Complete Healthcare
Communications. MediMedia Managed Markets is a leading provider of
strategic payer-validated market access solutions. Complete
Healthcare Communications is one of the leading medical and
scientific communication agencies working with medical affairs,
commercial and brand development teams within life science
companies. The acquisition agreement also provided for certain
working capital targets to be achieved by MediMedia Pharma
Solutions.
The acquisition of MediMedia Pharma Solutions has been accounted
for as a business combination in accordance with FASB ASC 805
Business Combinations. The following table summarizes the
Company’s estimate of the fair values of the assets acquired
and liabilities assumed:
Acquisitions - Aptiv Solutions
On May 7, 2014 the Company acquired 100% of the common stock of
Aptiv Solutions (“Aptiv”), a global biopharmaceutical
and medical device development services company and leader in
adaptive clinical trials for cash consideration of $143.5 million,
including certain payments to be made on behalf of the company on
completion totaling $22.4 million. The acquisition agreement
provided for working capital targets to be achieved. On March
25, 2015, the Company received $2.0 million in respect of these
targets on completion of the working capital review. Aptiv
offers full-service clinical trial consulting and regulatory
support for drugs, medical devices and diagnostics with a specific
focus on strategies to increase product development efficiency and
productivity. It is a market leader in the integrated design and
execution of adaptive clinical trials for exploratory and late
phase development as well as being an industry leader in medical
device and diagnostic development in key medical technology
segments.
The acquisition of Aptiv has been accounted for as a business
combination in accordance with FASB ASC 805
Business Combinations. The following table summarizes the
fair values of the assets acquired and the liabilities
assumed:
*Goodwill represents the acquisition of an established workforce
with experience in clinical trial consulting and regulatory support
for the development of drugs, medical devices and diagnostics, with
a specific focus on strategy to increase efficiency and
productivity in product development. Goodwill related to the
US portion of the business acquired is tax deductible.
**Adjustments to cash consideration represent certain one-time
liabilities (including loan notes) identified at the acquisition
date which have subsequently been paid.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Restructuring |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Restructuring |
4. Restructuring
Restructuring Charges
A restructuring charge of $4.1 million was recognized during the
three months ended September 30, 2016 ($8.2 million for the nine
months ended September 30, 2016) under a restructuring plan adopted
following a review by the company of its operations. The
restructuring plan includes resource rationalizations in certain
areas of the business to improve resource utilization, resulting in
a charge of $2.1 million, and office consolidation which results in
the recognition of an onerous lease obligation of $2.0
million.
Details of the restructuring charge recognized in the three and
nine months ended September 30, 2016 are as follows:
Details of the movement in the restructuring charge recognized in
the three and nine months ended 30 September 2016 are as
follows;
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Income Taxes |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Taxes |
5. Income Taxes
Income taxes recognized during the three and nine months ended
September 30, 2016 comprise:
As at September 30, 2016 the Company maintains a $34.1 million
liability (December 31, 2015: $31.4 million) for unrecognized tax
benefit, which is comprised of $30.4 million (December 31, 2015:
$28.1 million) related to items generating unrecognized tax
benefits and $3.7 million (December 31, 2015: $3.3 million) for
interest and related penalties to such items. The Company
recognizes interest accrued on unrecognized tax benefits as an
additional income tax expense.
The Company has analyzed filing positions in all of the significant
federal, state and foreign jurisdictions where it is required to
file income tax returns, as well as open tax years in these
jurisdictions. The only periods subject to examination by the major
tax jurisdictions where the Company does business are 2011 through
2015 tax years. The Company does not believe that the outcome of
any examination will have a material impact on its financial
statements.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Net income per ordinary share |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income per ordinary share |
6. Net income per ordinary share
Basic net income per ordinary share has been computed by dividing
net income available to ordinary shareholders by the weighted
average number of ordinary shares outstanding during the period.
Diluted net income per ordinary share is computed by adjusting the
weighted average number of ordinary shares outstanding during the
period for all potentially dilutive ordinary shares outstanding
during the period and adjusting net income for any changes in
income or loss that would result from the conversion of such
potential ordinary shares. There is no difference in net income
used for basic and diluted net income per ordinary share.
The reconciliation of the number of shares used in the computation
of basic and diluted net income per ordinary share is as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for earnings per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Share-based Awards |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based Awards |
7. Share-based Awards
Share Options
On July 21, 2008 the Company adopted the Employee Share Option Plan
2008 (the “2008 Employee Plan”) pursuant to which the
Compensation and Organization Committee of the Company’s
Board of Directors may grant options to any employee, or any
Director holding a salaried office or employment with the Company
or a Subsidiary for the purchase of ordinary shares. On the same
date, the Company also adopted the Consultants Share Option Plan
2008 (the “2008 Consultants Plan”), pursuant to which
the Compensation and Organization Committee of the Company’s
Board of Directors may grant options to any consultant, adviser or
non-executive Director retained by the Company or any Subsidiary
for the purchase of ordinary shares.
Each option granted under the 2008 Employee Plan or the 2008
Consultants Plan (together the “2008 Option Plans”)
will be an employee stock option, or Non-qualifying Stock Options
(‘NSO’), as described in Section 422 or 423 of the
Internal Revenue Code. Each grant of an option under the 2008
Options Plans will be evidenced by a Stock Option Agreement between
the optionee and the Company. The exercise price will be specified
in each Stock Option Agreement, however option prices will not be
less than 100% of the fair market value of an ordinary share on the
date the option is granted.
An aggregate of 6.0 million ordinary shares have been reserved
under the 2008 Employee Plan, as reduced by any shares issued or to
be issued pursuant to options granted under the 2008 Consultants
Plan, under which a limit of 400,000 shares applies. Further,
the maximum number of ordinary shares with respect to which options
may be granted under the 2008 Employee Option Plan, during any
calendar year to any employee shall be 400,000 ordinary
shares. There is no individual limit under the 2008
Consultants Plan. No options may be granted under the
2008 Option Plans after July 21, 2018.
On January 17, 2003 the Company adopted the Share Option Plan 2003
(the “2003 Share Option Plan”) pursuant to which the
Compensation and Organization Committee of the Board could grant
options to officers and other employees of the Company or its
subsidiaries for the purchase of ordinary shares. An
aggregate of 6.0 million ordinary shares were reserved under the
2003 Share Option Plan; and, in no event could the number of
ordinary shares issued pursuant to options awarded under this plan
exceed 10% of the outstanding shares, as defined in the 2003 Share
Option Plan, at the time of the grant, unless the Board expressly
determined otherwise. Further, the maximum number of ordinary
shares with respect to which options could be granted under the
2003 Share Option Plan during any calendar year to any employee was
400,000 ordinary shares. The 2003 Share Option Plan expired
on January 17, 2013. No new options may be granted under this
plan.
Share option awards are granted with an exercise price equal to the
market price of the Company’s shares at date of grant.
Share options typically vest over a period of five years from date
of grant and expire eight years from date of grant. The
maximum contractual term of options outstanding at September 30,
2016 is eight years.
The following table summarizes option activity for the nine
months ended September 30, 2016:
The Company has outstanding options with fair values ranging from
$6.19 to $20.78 per option or a weighted average fair value of
$10.62 per option. The Company issues ordinary shares for all
options exercised. The total amount of fully vested share options
which remained outstanding at September 30, 2016, was 739,901.
Fully vested share options at September 30, 2016, have an average
remaining contractual term of 3.38 years, an average exercise price
of $29.35 and a total intrinsic value of $35.5 million. The total
intrinsic value of options exercised during the nine months ended
September 30, 2016 was $12.5 million (September 30, 2015: $30.5
million).
The following table summarizes the movement in non-vested share
options for the nine months ended September 30, 2016:
Fair value of Stock Options Assumptions
The weighted average fair value of options granted during the nine
months ended September 30, 2016 and September 30, 2015 was
calculated using the Black-Scholes option pricing model. The
weighted average fair values and assumptions used were as
follows:
Expected volatility is based on the historical volatility of our
common stock over a period equal to the expected term of the
options; the expected life represents the weighted average period
of time that options granted are expected to be outstanding given
consideration to vesting schedules and our historical experience of
past vesting and termination patterns. The risk-free rate is based
on the U.S. government zero-coupon bonds yield curve in effect at
time of the grant for periods corresponding with the expected life
of the option.
Restricted Share Units and Performance Share Units
On July 21, 2008 the Company adopted the 2008 Employees Restricted
Share Unit Plan (the “2008 RSU Plan”) pursuant to which
the Compensation and Organization Committee of the Company’s
Board of Directors may select any employee, or any Director holding
a salaried office or employment with the Company, or a Subsidiary
to receive an award under the plan. An aggregate of 1.0
million ordinary shares have been reserved for issuance under the
2008 RSU Plan.
On April 23, 2013 the Company adopted the 2013 Employees Restricted
Share Unit and Performance Share Unit Plan (the “2013 RSU
Plan”) pursuant to which the Compensation and Organization
Committee of the Company’s Board of Directors may select any
employee, or any Director holding a salaried office or employment
with the Company, or a Subsidiary to receive an award under the
plan. On May 11, 2015 the 2013 RSU Plan was amended and
restated in order to increase the number of shares that can be
issued under the RSU Plan by 2.5 million shares. Accordingly,
an aggregate of 4.1 million ordinary shares have been reserved for
issuance under the 2013 RSU Plan. The shares are awarded at
par value and vest over a service period. Awards under the 2013 RSU
Plan may be settled in cash or shares at the option of the
Company.
The Company has awarded RSUs and PSUs to certain key individuals of
the Group. The following table summarizes RSU and PSU activity for
the nine months ended September 30, 2016:
The fair value of RSUs vested for the nine months ended September
30, 2016 totaled $10.5 million (full year 2015: $7.0
million).
The fair value of PSUs vested for the nine months ended September
30, 2016 totaled $10.3 million (the fair value of PSUs vested for
the full year 2015 was $0.3 million).
The PSUs vest based on service and specified EPS targets over the
period 2013 – 2016, 2014 – 2017, 2015 – 2018 and
2016 - 2019. Since 2013, 421,079 PSUs (net of forfeitures) have
been granted. Depending on the actual amount of EPS from 2013
to 2019, up to an additional 409,444 PSUs may also be
granted.
Non-cash stock compensation expense
Non-cash stock compensation expense for the three and nine months
ended September 30, 2016 has been allocated as follows:
Total non-cash stock compensation expense not yet recognized at
September 30, 2016 amounted to $76.1 million. The weighted
average period over which this is expected to be recognized is 2.2
years . Total tax benefit
recognized in additional paid in capital related to the non-cash
compensation expense amounted to $5.4 million for the nine months
ended September 30, 2016 (September 30, 2015: $3.0 million).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Business Segment Information |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Segment Information |
8. Business Segment Information
The Company determines and presents operating segments based on the
information that is internally provided to the Chief Executive
Officer, Chief Financial Officer and Chief Operating Officer, who
together are considered the Company’s chief operating
decision maker, in accordance with FASB ASC 280-10
Disclosures about Segments of an Enterprises and Related
Information.
The Company is a contract research organization
(“CRO”), providing outsourced development services on a
global basis to the pharmaceutical, biotechnology and medical
device industries. It specializes in the strategic development,
management and analysis of programs that support all stages of the
clinical development process - from compound selection to Phase
I-IV clinical studies. The Company has the expertise and
capability to conduct clinical trials in most major therapeutic
areas on a global basis and has the operational flexibility to
provide development services on a stand-alone basis or as part of
an integrated “full service” solution. The
Company has expanded predominately through internal growth,
together with a number of strategic acquisitions to enhance its
expertise and capabilities in certain areas of the clinical
development process.
The Company is generally awarded projects based upon responses to
requests for proposals received from companies in the
pharmaceutical, biotechnology and medical device industries or work
orders executed under our strategic partnership arrangements.
Contracts with customers are generally entered into centrally, in
most cases with ICON Clinical Research Limited (“ICON
Ireland”), the Company’s principal operating subsidiary
in Ireland. Revenues, which consist primarily of fees earned
under these contracts, are allocated to individual entities within
the Group, based on where the work is performed in accordance with
the Company’s global transfer pricing model.
ICON Ireland acts as the group entrepreneur under the
Company’s global transfer pricing model given its role in the
development and management of the group, it’s ownership of
key intellectual property and customer relationships, its key role
in the mitigation of risks faced by the group and its
responsibility for maintaining the Company’s global
network. As such it enters into the majority of the
Company’s customer contracts.
ICON Ireland remunerates other operating entities in the ICON Group
on the basis of a guaranteed cost plus mark up for the services
they perform in each of their local territories. The cost
plus mark up for each ICON entity is established to ensure that
each of ICON Ireland and the ICON entities that are involved in the
conduct of services for customers, earn an appropriate arms-length
return having regard to the assets owned, risks borne, and
functions performed by each entity from these intercompany
transactions. The cost plus mark-up policy is reviewed annually to
ensure that it is market appropriate.
The geographic split of revenue disclosed for each region outside
Ireland is the cost plus revenue attributable to these entities.
The residual revenues of the Group, once each ICON entity has been
paid its respective intercompany service fee, generally fall to be
retained by ICON Ireland. As such revenues and income from
operations in Ireland are a function of this global transfer
pricing model and comprise net revenues of the Group after
deducting the cost plus revenues attributable to the activities
performed outside Ireland.
The Company's areas of operation outside of Ireland include the
United States, United Kingdom, France, Germany, Italy, Spain, The
Netherlands, Sweden, Turkey, Poland, Czech Republic, Latvia,
Russia, Ukraine, Hungary, Israel, Romania, Switzerland, Canada,
Mexico, Brazil, Colombia, Argentina, Chile, Peru, India, China,
South Korea, Japan, Thailand, Taiwan, Singapore, The Philippines,
Australia, New Zealand, and South Africa.
Segment information as at September 30, 2016 and December 31, 2015
and for the three and nine months ended September 30, 2016 and
September 30, 2015 is as follows:
a) The distribution of net revenue by geographical area was as
follows:
*
All sales shown for Ireland are export sales.
b) The distribution of income from operations, including
restructuring, by geographical area was as follows:
c) The distribution of income from operations, excluding
restructuring, by geographical area was as follows:
d) The distribution of property, plant and equipment, net, by
geographical area was as follows:
e) The distribution of depreciation and amortization by
geographical area was as follows:
f) The distribution of total assets by geographical area was as
follows:
*
The December 31, 2015 Balance Sheet has been retrospectively
restated as required to reflect the requirements of new guidance in
respect of the presentation of debt issue costs.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Goodwill (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Business Combinations (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clinical Research Management Inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed | The table following summarizes the Company’s provisional
estimates of the fair values of the assets acquired and liabilities
assumed:
*Goodwill represents the acquisition of an established workforce
with experience in preclinical through Phase IV support of clinical
research and clinical trial services for biologics, drugs and
devices.
**The Company has made an initial estimate of separate intangible
assets acquired of $9.8 million. This assessment is under
review and will be finalized within 12 months of the date of
acquisition.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PMG | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed |
The acquisition of PMG has been accounted for as a business
combination in accordance with FASB ASC 805
Business Combinations. The Company has made a
provisional assessment of the fair value of assets acquired and
liabilities assumed as at that date. The table following
summarizes the Company’s provisional estimates of the fair
values of the assets acquired and liabilities assumed:
*Goodwill represents the acquisition of an established workforce
with experience in clinical trial consulting and regulatory support
for the development of drugs, medical devices and diagnostics, with
a specific focus on strategy to increase efficiency and
productivity in product development.
**The Company has made an initial estimate of separate intangible
assets acquired, being customer lists and order backlog, of $10.6
million. This assessment is under review and will be
finalized within 12 months of the date of acquisition.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| MediMedia Pharma Solutions | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed |
The following table summarizes the Company’s estimate of the
fair values of the assets acquired and liabilities assumed:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Aptiv Solutions | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed |
The following table summarizes the fair values of the assets
acquired and the liabilities assumed:
*Goodwill represents the acquisition of an established workforce
with experience in clinical trial consulting and regulatory support
for the development of drugs, medical devices and diagnostics, with
a specific focus on strategy to increase efficiency and
productivity in product development. Goodwill related to the
US portion of the business acquired is tax deductible.
**Adjustments to cash consideration represent certain one-time
liabilities (including loan notes) identified at the acquisition
date which have subsequently been paid.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Restructuring (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Details of restructuring charge recognized |
Details of the restructuring charge recognized in the three and
nine months ended September 30, 2016 are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Details of Movement in Restructuring Provisions Recognized |
Details of the movement in the restructuring charge recognized in
the three and nine months ended 30 September 2016 are as
follows;
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Restructuring Charges. No definition available.
|
| X | ||||||||||
- Definition Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Income Taxes (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Taxes Recognized During Period |
Income taxes recognized during the three and nine months ended
September 30, 2016 comprise:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Net income per ordinary share (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share |
The reconciliation of the number of shares used in the computation
of basic and diluted net income per ordinary share is as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Share-based Awards (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Stock Option Activity |
The following table summarizes option activity for the nine
months ended September 30, 2016:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Movement in Non-Vested Share Options |
The following table summarizes the movement in non-vested share
options for the nine months ended September 30, 2016:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Weighted Average Fair Values and Assumptions Used |
The weighted average fair values and assumptions used were as
follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RSU and PSU Activity |
The following table summarizes RSU and PSU activity for the nine
months ended September 30, 2016:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Non-cash Stock Compensation Expense |
Non-cash stock compensation expense for the three and nine months
ended September 30, 2016 has been allocated as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Schedule of Non Cash Stock Compensation Expense. No definition available.
|
| X | ||||||||||
- Definition Schedule Of Share Based Compensation Restricted Stock Units Performance Stock Units Award Activity [Table Text Block] No definition available.
|
| X | ||||||||||
- Definition Tabular disclosure of the changes in outstanding nonvested shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Business Segment Information (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Net Revenue by Geographical Area |
a) The distribution of net revenue by geographical area was as
follows:
*
All sales shown for Ireland are export sales.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Income from Operations by Geographical Area |
b) The distribution of income from operations, including
restructuring, by geographical area was as follows:
c) The distribution of income from operations, excluding
restructuring, by geographical area was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Property, Plant and Equipment, Net, by Geographical Area |
d) The distribution of property, plant and equipment, net, by
geographical area was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Depreciation and Amortization by Geographical Area |
e) The distribution of depreciation and amortization by
geographical area was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Total Assets by Geographical Area |
f) The distribution of total assets by geographical area was as
follows:
*
The December 31, 2015 Balance Sheet has been retrospectively
restated as required to reflect the requirements of new guidance in
respect of the presentation of debt issue costs.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- Definition Operating Income by Geography. No definition available.
|
| X | ||||||||||
- Definition Schedule Of Depreciation And Amortization Expense By Geographical Area. No definition available.
|
| X | ||||||||||
- Definition Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Goodwill (Detail) - USD ($) $ in Thousands |
9 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|
Sep. 30, 2016 |
Dec. 31, 2015 |
|||||
| Goodwill [Line Items] | ||||||
| Opening balance | $ 588,434 | [1] | $ 463,324 | |||
| Current period acquisitions (Note 3) | 39,376 | 133,123 | ||||
| Prior period acquisitions (Note 3) | 5,403 | 4,418 | ||||
| Foreign exchange movement | (6,556) | (12,431) | ||||
| Closing balance | $ 626,657 | $ 588,434 | [1] | |||
| ||||||
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) from foreign currency translation adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Business Combinations - Additional Information (Detail) $ in Thousands |
1 Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 15, 2016
USD ($)
|
Mar. 31, 2016
USD ($)
|
Dec. 04, 2015
USD ($)
Patient
Site
|
Mar. 25, 2015
USD ($)
|
Feb. 27, 2015
USD ($)
|
May 07, 2014
USD ($)
|
Apr. 30, 2016
USD ($)
|
||||||
| PMG | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Net cash outflow | $ 63,500 | |||||||||||
| Other liabilities assumed | $ 9,860 | |||||||||||
| Number of clinical research sites acquired | Site | 48 | |||||||||||
| Working capital targets achievement period | 90 days | |||||||||||
| Working capital adjustment | $ 1,600 | $ 1,613 | ||||||||||
| Working capital adjustment, cash paid | $ 1,613 | |||||||||||
| Cash consideration | $ 53,681 | |||||||||||
| PMG | Minimum | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Number of active patients via electronic medical records acquired | Patient | 2,000,000 | |||||||||||
| MediMedia Pharma Solutions | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Net cash outflow | $ 116,002 | |||||||||||
| Other liabilities assumed | [1] | 11,283 | ||||||||||
| Working capital adjustment | 3,998 | |||||||||||
| Cash consideration, net of working capital adjustment | 104,700 | |||||||||||
| Cash consideration | $ 108,717 | |||||||||||
| Aptiv Solutions | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Working capital adjustment | $ 2,000 | $ 1,964 | ||||||||||
| Percentage of common stock acquired | 100.00% | |||||||||||
| Cash consideration | $ 143,500 | |||||||||||
| Adjustments to cash consideration | [2] | $ 22,399 | ||||||||||
| Clinical Research Management Inc. | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Net cash outflow | $ 52,400 | |||||||||||
| Other liabilities assumed | 9,200 | |||||||||||
| Maximum additional consideration that might be payable | 12,000 | |||||||||||
| Cash consideration | $ 52,396 | |||||||||||
| ||||||||||||
| X | ||||||||||
- Definition Business Acquisition Additional Cash Paid For Working Capital Adjustment No definition available.
|
| X | ||||||||||
- Definition The working capital adjustment was received in October 2013 however it relates to the purchase of Cross Country Healthcare Inc on 15 February 2013, and is disclosed as part of net assets acquired on this date. No definition available.
|
| X | ||||||||||
- Definition Number of Clinical Research Sites Acquired No definition available.
|
| X | ||||||||||
- Definition Number of Patients No definition available.
|
| X | ||||||||||
- Definition Working Capital Targets Achievement Period No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of Clinical Research Management, Inc. (Detail) - USD ($) $ in Thousands |
Sep. 15, 2016 |
Sep. 30, 2016 |
Dec. 31, 2015 |
[1] | Dec. 31, 2014 |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Business Acquisition [Line Items] | ||||||||||||
| Goodwill | $ 626,657 | $ 588,434 | $ 463,324 | |||||||||
| Clinical Research Management Inc. | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Cash | $ 1,842 | |||||||||||
| Property, plant and equipment | 938 | |||||||||||
| Goodwill | [2] | 39,376 | ||||||||||
| Intangible assets | [3] | 9,844 | ||||||||||
| Accounts receivable | 11,815 | |||||||||||
| Unbilled revenue | 4,160 | |||||||||||
| Prepayments and other current assets | 2,012 | |||||||||||
| Accounts payable | (917) | |||||||||||
| Other liabilities | (4,667) | |||||||||||
| Non-current other liabilities | (7) | |||||||||||
| Net assets acquired | 64,396 | |||||||||||
| Cash consideration | 52,396 | |||||||||||
| Contingent consideration | $ 12,000 | |||||||||||
| ||||||||||||
| X | ||||||||||
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unbilled Revenue No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liability recognized arising from contingent consideration in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of property, plant, and equipment recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of Clinical Research Management, Inc. (Parenthetical) (Detail) $ in Thousands |
Sep. 15, 2016
USD ($)
|
|||
|---|---|---|---|---|
| Clinical Research Management Inc. | ||||
| Business Acquisition [Line Items] | ||||
| Intangible asset | $ 9,844 | [1] | ||
| ||||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of PMG (Detail) - USD ($) $ in Thousands |
9 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 |
Dec. 04, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
Dec. 31, 2015 |
[1] | Dec. 31, 2014 |
||||||||
| Business Acquisition [Line Items] | ||||||||||||||
| Goodwill | $ 626,657 | $ 588,434 | $ 463,324 | |||||||||||
| Total cash outflows | $ 54,009 | $ 102,756 | ||||||||||||
| PMG | ||||||||||||||
| Business Acquisition [Line Items] | ||||||||||||||
| Cash | $ 194 | |||||||||||||
| Property, plant and equipment | 712 | |||||||||||||
| Goodwill | [2] | 46,442 | ||||||||||||
| Intangible assets | [3] | 10,582 | ||||||||||||
| Accounts receivable | 12,747 | |||||||||||||
| Prepayments and other current assets | 1,329 | |||||||||||||
| Accounts payable | (530) | |||||||||||||
| Other liabilities | (2,656) | |||||||||||||
| Non-current deferred tax liability | (3,666) | |||||||||||||
| Net assets acquired | 65,154 | |||||||||||||
| Cash consideration | 53,681 | |||||||||||||
| Other liabilities assumed | 9,860 | |||||||||||||
| Working capital adjustment | $ 1,600 | 1,613 | ||||||||||||
| Total cash outflows | $ 65,154 | |||||||||||||
| ||||||||||||||
| X | ||||||||||
- Definition The working capital adjustment was received in October 2013 however it relates to the purchase of Cross Country Healthcare Inc on 15 February 2013, and is disclosed as part of net assets acquired on this date. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary differences due after one year or the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of property, plant, and equipment recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of PMG (Parenthetical) (Detail) - PMG $ in Thousands |
Dec. 04, 2015
USD ($)
|
|||
|---|---|---|---|---|
| Business Acquisition [Line Items] | ||||
| Intangible asset | $ 10,582 | [1] | ||
| Customer Lists | ||||
| Business Acquisition [Line Items] | ||||
| Intangible asset | $ 10,582 | |||
| ||||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of MediMedia Pharma Solutions (Detail) - USD ($) $ in Thousands |
Feb. 27, 2015 |
Sep. 30, 2016 |
Dec. 31, 2015 |
[1] | Dec. 31, 2014 |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Business Acquisition [Line Items] | ||||||||||||
| Goodwill | $ 626,657 | $ 588,434 | $ 463,324 | |||||||||
| MediMedia Pharma Solutions | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Property, plant and equipment | $ 1,049 | |||||||||||
| Goodwill | [2] | 92,084 | ||||||||||
| Accounts receivable | 5,240 | |||||||||||
| Unbilled revenue | 4,324 | |||||||||||
| Prepayments and other current assets | 621 | |||||||||||
| Accounts payable | (749) | |||||||||||
| Payments on account | (4,186) | |||||||||||
| Deferred tax liability | (2,171) | |||||||||||
| Other liabilities | (5,483) | |||||||||||
| Net assets acquired | 116,002 | |||||||||||
| Cash consideration | 108,717 | |||||||||||
| Other liabilities assumed | [3] | 11,283 | ||||||||||
| Gross cash outflows | 120,000 | |||||||||||
| Working capital adjustment | (3,998) | |||||||||||
| Net cash outflows | 116,002 | |||||||||||
| MediMedia Pharma Solutions | Customer Lists | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Intangible asset | 22,752 | |||||||||||
| MediMedia Pharma Solutions | Order Backlog | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Intangible asset | $ 2,521 | |||||||||||
| ||||||||||||
| X | ||||||||||
- Definition The working capital adjustment was received in October 2013 however it relates to the purchase of Cross Country Healthcare Inc on 15 February 2013, and is disclosed as part of net assets acquired on this date. No definition available.
|
| X | ||||||||||
- Definition Business Combination, Consideration Transferred, Gross No definition available.
|
| X | ||||||||||
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Payments on Account No definition available.
|
| X | ||||||||||
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unbilled Revenue No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary difference due within one year or the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of property, plant, and equipment recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of MediMedia Pharma Solutions (Parenthetical) (Detail) $ in Thousands |
Feb. 27, 2015
USD ($)
|
|||
|---|---|---|---|---|
| MediMedia Pharma Solutions | ||||
| Business Acquisition [Line Items] | ||||
| Other liabilities assumed | $ 11,283 | [1] | ||
| ||||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of Aptiv Solutions (Detail) - USD ($) $ in Thousands |
Mar. 25, 2015 |
May 07, 2014 |
Sep. 30, 2016 |
Dec. 31, 2015 |
[1] | Dec. 31, 2014 |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Business Acquisition [Line Items] | |||||||||||||
| Goodwill | $ 626,657 | $ 588,434 | $ 463,324 | ||||||||||
| Aptiv Solutions | |||||||||||||
| Business Acquisition [Line Items] | |||||||||||||
| Property, plant and equipment | $ 6,924 | ||||||||||||
| Goodwill | [2] | 125,627 | |||||||||||
| Cash and cash equivalents | 3,484 | ||||||||||||
| Accounts receivable | 25,091 | ||||||||||||
| Unbilled revenue | 21,154 | ||||||||||||
| Prepayments and other current assets | 4,180 | ||||||||||||
| Non-current assets | 2,911 | ||||||||||||
| Accounts payable | (9,565) | ||||||||||||
| Other liabilities | (29,782) | ||||||||||||
| Payments on account | (31,094) | ||||||||||||
| Non-current other liabilities | (11,303) | ||||||||||||
| Loan notes payable | [3] | (17,790) | |||||||||||
| Net assets acquired | 119,137 | ||||||||||||
| Cash consideration | 143,500 | ||||||||||||
| Working capital adjustment | $ (2,000) | (1,964) | |||||||||||
| Gross cash outflows | 141,536 | ||||||||||||
| Adjustments to cash consideration | [3] | (22,399) | |||||||||||
| Net assets acquired/Net purchase consideration | 119,137 | ||||||||||||
| Aptiv Solutions | Customer Relationships | |||||||||||||
| Business Acquisition [Line Items] | |||||||||||||
| Intangible asset | 21,400 | ||||||||||||
| Aptiv Solutions | Order Backlog | |||||||||||||
| Business Acquisition [Line Items] | |||||||||||||
| Intangible asset | $ 7,900 | ||||||||||||
| |||||||||||||
| X | ||||||||||
- Definition The working capital adjustment was received in October 2013 however it relates to the purchase of Cross Country Healthcare Inc on 15 February 2013, and is disclosed as part of net assets acquired on this date. No definition available.
|
| X | ||||||||||
- Definition Business Combination, Consideration Transferred, Gross No definition available.
|
| X | ||||||||||
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Payments on Account No definition available.
|
| X | ||||||||||
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Unbilled Revenue No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of property, plant, and equipment recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Restructuring - Additional Information (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | |
|---|---|---|---|
Sep. 30, 2016 |
Jun. 30, 2016 |
Sep. 30, 2016 |
|
| Restructuring Cost and Reserve [Line Items] | |||
| Restructuring charges | $ 4,065 | $ 4,094 | $ 8,159 |
| Workforce reduction | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Restructuring charges | 2,096 | $ 4,094 | 6,190 |
| Office Consolidations | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Restructuring charges | $ 1,969 | $ 1,969 | |
| X | ||||||||||
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Details of restructuring charge recognized (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | |
|---|---|---|---|
Sep. 30, 2016 |
Jun. 30, 2016 |
Sep. 30, 2016 |
|
| Restructuring Cost and Reserve [Line Items] | |||
| Restructuring charges | $ 4,065 | $ 4,094 | $ 8,159 |
| Total | $ 4,065 | $ 8,159 | |
| X | ||||||||||
- Definition Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations net of research and development incentives. No definition available.
|
| X | ||||||||||
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
Details of Movement in Restructuring Provisions Recognized (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | |
|---|---|---|---|
Sep. 30, 2016 |
Jun. 30, 2016 |
Sep. 30, 2016 |
|
| Restructuring Cost and Reserve [Line Items] | |||
| Initial restructuring charge recorded | $ 4,065 | $ 4,094 | $ 8,159 |
| Cash payments | (2,243) | (901) | (3,144) |
| Foreign exchange movement | 0 | ||
| Closing provision | 5,015 | 3,193 | 5,015 |
| Workforce reduction | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Initial restructuring charge recorded | 2,096 | 4,094 | 6,190 |
| Cash payments | (2,243) | (901) | (3,144) |
| Foreign exchange movement | 0 | ||
| Closing provision | 3,046 | $ 3,193 | 3,046 |
| Office Consolidations | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Initial restructuring charge recorded | 1,969 | 1,969 | |
| Foreign exchange movement | 0 | ||
| Closing provision | $ 1,969 | $ 1,969 | |
| X | ||||||||||
- Definition Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of gain (loss) from translating a restructuring reserve to the currency of the reporting entity from an amount denominated or measured in a different currency. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Income Taxes Recognized During Period (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
|
| Reconciliation of Provision of Income Taxes [Line Items] | ||||
| Provision for income taxes before restructuring and other items | $ 10,979 | $ 9,196 | $ 31,669 | $ 29,534 |
| Tax impact of restructuring and other items | (509) | (1,020) | ||
| Provision for income taxes after restructuring and other items | $ 10,470 | $ 9,196 | $ 30,649 | $ 29,534 |
| X | ||||||||||
- Definition Income Tax Expense Benefit Before Restructuring And Other Items No definition available.
|
| X | ||||||||||
- Definition Reconciliation of Provision of Income Taxes [Line Items] No definition available.
|
| X | ||||||||||
- Definition Tax Impact Of Restructuring And Other Items No definition available.
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Income Taxes - Additional Information (Detail) - USD ($) $ in Millions |
9 Months Ended | |
|---|---|---|
Sep. 30, 2016 |
Dec. 31, 2015 |
|
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||
| Liability for unrecognized tax benefit | $ 34.1 | $ 31.4 |
| Items generating unrecognized tax benefits | 30.4 | 28.1 |
| Interest and related penalties | $ 3.7 | $ 3.3 |
| Earliest Tax Year | ||
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||
| Tax year subject to examination by major tax jurisdictions | 2011 | |
| Latest Tax Year | ||
| Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||
| Tax year subject to examination by major tax jurisdictions | 2015 |
| X | ||||||||||
- Definition Unrecognized Tax Benefits, Current Year Tax Positions No definition available.
|
| X | ||||||||||
- Definition Tax year that remains open to examination under enacted tax laws, in CCYY format. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share (Detail) - shares |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
|
| Schedule of Weighted Average Number of Diluted Shares Outstanding [Line Items] | ||||
| Weighted average number of ordinary shares outstanding for basic net income per ordinary share | 55,734,773 | 58,659,782 | 55,355,020 | 59,728,608 |
| Effect of dilutive share options outstanding | 910,466 | 1,710,116 | 1,120,299 | 2,057,241 |
| Weighted average number of ordinary shares outstanding for diluted net income per ordinary share | 56,645,239 | 60,369,898 | 56,475,319 | 61,785,849 |
| X | ||||||||||
- Definition Schedule of Weighted Average Number of Diluted Shares Outstanding [Line Items] No definition available.
|
| X | ||||||||||
- Definition The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
Share-based Awards - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands |
9 Months Ended | 12 Months Ended | 42 Months Ended | ||
|---|---|---|---|---|---|
May 11, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
Dec. 31, 2015 |
Jun. 30, 2016 |
|
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
| Non-cash stock compensation expense not yet recognized | $ 76,100 | ||||
| Unrecognized stock-based compensation expense, weighted average period (years) | 2 years 2 months 12 days | ||||
| Tax benefit on exercise of options | $ 5,381 | $ 3,014 | |||
| Restricted Stock Units (RSUs) | |||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
| Fair value of stock units vested | $ 10,500 | $ 7,000 | |||
| Stock units granted | 373,630 | ||||
| Performance Share Unit (PSUs) | |||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
| Fair value of stock units vested | $ 10,300 | $ 300 | |||
| Stock units granted | 247,992 | ||||
| PSUs Based on Service and EPS Targets | |||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
| Stock units granted | 421,079 | ||||
| PSUs Based on Service and EPS Targets | Minimum | |||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
| Cumulative EPS vesting period | 2013 | ||||
| PSUs Based on Service and EPS Targets | Maximum | |||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
| Stock units to be granted | 409,444 | ||||
| Cumulative EPS vesting period | 2019 | ||||
| Employee Stock Plan, 2008 Plan | |||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
| Ordinary shares which have been reserved for issuance | 6,000,000 | ||||
| Employee Stock Plan, 2008 Plan | Individual Employee | |||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
| Ordinary shares which have been reserved for issuance | 400,000 | ||||
| Employee Stock Plan, 2008 Plan | Minimum | |||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
| Percentage of option price for fair value of ordinary share | 100.00% | ||||
| Employee Stock Plan, 2003 Plan | |||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
| Ordinary shares which have been reserved for issuance | 6,000,000 | ||||
| Maximum number of award as percentage of shares outstanding | 10.00% | ||||
| Employee Stock Plan, 2003 Plan | Individual Employee | |||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
| Ordinary shares which have been reserved for issuance | 400,000 | ||||
| Employee Stock Option | |||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
| Shares vesting period | 5 years | ||||
| Shares expiration period | 8 years | ||||
| Weighted average contractual term of options outstanding | 4 years 8 months 19 days | ||||
| Weighted average fair value per option | $ 10.62 | ||||
| Exercisable - number of shares | 739,901 | ||||
| Exercisable - weighted average remaining contractual life | 3 years 4 months 17 days | ||||
| Exercisable - weighted average exercise price | $ 29.35 | ||||
| Fully vested total intrinsic value | $ 35,500 | ||||
| Intrinsic value of option exercised | $ 12,500 | $ 30,500 | |||
| Employee Stock Option | Minimum | |||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
| Options outstanding fair value | $ 6.19 | ||||
| Employee Stock Option | Maximum | |||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
| Weighted average contractual term of options outstanding | 8 years | ||||
| Options outstanding fair value | $ 20.78 | ||||
| Restricted Stock Units 2008 | |||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
| Ordinary shares which have been reserved for issuance | 1,000,000 | ||||
| Restricted Stock Units 2013 | |||||
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||
| Ordinary shares which have been reserved for issuance | 4,100,000 | ||||
| Number of additional shares authorized for issuance | 2,500,000 | ||||
| X | ||||||||||
- Definition Compensation Related Costs Share Based Payments Disclosure [Line Items] No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period, Weighted Average Option Price No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Option Price No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award Other Than Options Expected Vesting Period No definition available.
|
| X | ||||||||||
- Definition Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Unrecognized cost of unvested share-based compensation awards. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of additional shares authorized for issuance under an established share-based compensation plan. No definition available.
|
| X | ||||||||||
- Definition The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock. No definition available.
|
| X | ||||||||||
- Definition Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Purchase price of common stock expressed as a percentage of its fair value. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Summary of Stock Option Activity (Detail) - Employee Stock Option - $ / shares |
9 Months Ended | |
|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
|
| Options Outstanding Number of Shares | ||
| Outstanding at beginning of period | 1,626,582 | |
| Granted | 256,191 | |
| Exercised | (268,713) | |
| Forfeited | (19,825) | |
| Outstanding at end of period | 1,594,235 | |
| Exercisable at end of period | 739,901 | |
| Weighted Average Exercise Price | ||
| Outstanding at beginning of period | $ 34.87 | |
| Granted | 69.61 | |
| Exercised | 26.81 | |
| Forfeited | 30.96 | |
| Outstanding at end of period | 41.86 | |
| Exercisable at end of period | 29.35 | |
| Weighted Average Fair Value | ||
| Outstanding at beginning of period | 11.94 | |
| Granted | 20.10 | $ 19.75 |
| Exercised | 10.10 | |
| Forfeited | 11.47 | |
| Outstanding at end of period | 13.57 | |
| Exercisable at end of period | $ 10.63 | |
| Weighted Average Remaining Contractual Life | ||
| Outstanding at end of period | 4 years 8 months 19 days | |
| Exercisable at end of period | 3 years 4 months 17 days | |
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Forfeited in Period, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Options, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
- Definition Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract] No definition available.
|
| X | ||||||||||
- Definition Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Grant Date Fair Value [Abstract] No definition available.
|
| X | ||||||||||
- Definition The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Gross number of share options (or share units) granted during the period. No definition available.
|
| X | ||||||||||
- Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of options outstanding, including both vested and non-vested options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. No definition available.
|
| X | ||||||||||
- Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Weighted average price at which option holders acquired shares when converting their stock options into shares. No definition available.
|
| X | ||||||||||
- Definition Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. No definition available.
|
| X | ||||||||||
- Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. No definition available.
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of share options (or share units) exercised during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Summary of Movement in Non-Vested Share Options (Detail) - Employee Stock Option - $ / shares |
9 Months Ended | |
|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
|
| Options Outstanding Number of Shares | ||
| Beginning Balance | 968,853 | |
| Granted | 256,191 | |
| Vested | (353,888) | |
| Forfeited | (16,822) | |
| Ending Balance | 854,334 | |
| Weighted Average Exercise Price | ||
| Beginning balance | $ 42.14 | |
| Granted | 69.61 | |
| Vested | 37.04 | |
| Forfeited | 32.27 | |
| Ending balance | 52.69 | |
| Weighted Average Fair Value | ||
| Beginning Balance | 13.69 | |
| Granted | 20.10 | $ 19.75 |
| Vested | 12.58 | |
| Forfeited | 11.78 | |
| Ending Balance | $ 16.11 | |
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Forfeited in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Granted in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Outstanding Exercise Price Abstract No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Outstanding Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
- Definition Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Vested in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
- Definition Gross number of share options (or share units) granted during the period. No definition available.
|
| X | ||||||||||
- Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of non-vested options outstanding. No definition available.
|
| X | ||||||||||
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. No definition available.
|
| X | ||||||||||
- Definition Number of non-vested options forfeited. No definition available.
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of non-vested options forfeited. No definition available.
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of non-vested options outstanding. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Number of options vested. No definition available.
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of options vested. No definition available.
|
| X | ||||||||||
- Details
|
Schedule of Weighted Average Fair Values and Assumptions Used (Detail) - Employee Stock Option - $ / shares |
9 Months Ended | |
|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
| Weighted average fair value | $ 20.10 | $ 19.75 |
| Assumptions: | ||
| Expected volatility | 30.00% | 30.00% |
| Dividend yield | 0.00% | 0.00% |
| Risk-free interest rate | 1.39% | 1.58% |
| Expected life | 5 years | 5 years |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The risk-free interest rate assumption that is used in valuing an option on its own shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
Summary of RSU and PSU Activity (Detail) - $ / shares |
9 Months Ended | 12 Months Ended |
|---|---|---|
Sep. 30, 2016 |
Dec. 31, 2015 |
|
| Performance Share Unit (PSUs) | ||
| Outstanding Number of Shares | ||
| Outstanding at beginning of period | 901,773 | |
| Granted | 247,992 | |
| Shares vested | (311,492) | |
| Forfeited | (7,750) | |
| Outstanding at ending of period | 830,523 | 901,773 |
| Weighted Average Fair Value | ||
| Outstanding at beginning of period | $ 48.33 | |
| Granted | 71.58 | |
| Shares vested | 33.09 | |
| Forfeited | 56.58 | |
| Outstanding at end of period | $ 60.73 | $ 48.33 |
| Weighted Average Remaining Contractual Life | ||
| Outstanding at end of period | 1 year 4 months 10 days | 1 year 2 months 19 days |
| Restricted Stock Units (RSUs) | ||
| Outstanding Number of Shares | ||
| Outstanding at beginning of period | 1,067,613 | |
| Granted | 373,630 | |
| Shares vested | (292,229) | |
| Forfeited | (108,504) | |
| Outstanding at ending of period | 1,040,510 | 1,067,613 |
| Weighted Average Fair Value | ||
| Outstanding at beginning of period | $ 48.30 | |
| Granted | 66.93 | |
| Shares vested | 35.92 | |
| Forfeited | 51.96 | |
| Outstanding at end of period | $ 58.09 | $ 48.30 |
| Weighted Average Remaining Contractual Life | ||
| Outstanding at end of period | 1 year 7 months 13 days | 1 year 5 months 23 days |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. No definition available.
|
| X | ||||||||||
- Definition The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. No definition available.
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Schedule of Non-cash Stock Compensation Expense (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
| Share-based compensation expense | $ 10,445 | $ 9,031 | $ 31,135 | $ 24,043 |
| Direct costs | ||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
| Share-based compensation expense | 5,755 | 4,976 | 16,830 | 12,942 |
| Selling, general and administrative | ||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
| Share-based compensation expense | $ 4,690 | $ 4,055 | $ 14,305 | $ 11,101 |
| X | ||||||||||
- Definition The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution of Net Revenue by Geographical Area (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
|
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | $ 420,201 | $ 394,741 | $ 1,231,353 | $ 1,171,629 |
| Ireland | ||||
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | 97,299 | 113,060 | 293,787 | 332,563 |
| Rest Of Europe | ||||
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | 76,427 | 79,077 | 231,505 | 241,705 |
| United States | ||||
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | 204,265 | 161,144 | 581,732 | 475,508 |
| Rest of World | ||||
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | $ 42,210 | $ 41,460 | $ 124,329 | $ 121,853 |
| X | ||||||||||
- Definition Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution of Income from operations, including Restructuring, by Geographical Are (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
|
| Segment Reporting Information [Line Items] | ||||
| Income from operations | $ 77,114 | $ 71,385 | $ 227,051 | $ 206,191 |
| Ireland | ||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations | 63,933 | 56,612 | 178,081 | 153,620 |
| Rest Of Europe | ||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations | 837 | 3,871 | 9,144 | 14,178 |
| United States | ||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations | 11,471 | 8,129 | 34,081 | 30,576 |
| Rest of World | ||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations | $ 873 | $ 2,773 | $ 5,745 | $ 7,817 |
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution of Income from operations, excluding Restructuring, by Geographical Area (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
|
| Segment Reporting Information [Line Items] | ||||
| Income from operations, excluding restructuring and other items | $ 81,179 | $ 71,385 | $ 235,210 | $ 206,191 |
| Ireland | ||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations, excluding restructuring and other items | 64,821 | 56,612 | 182,698 | 153,620 |
| Rest Of Europe | ||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations, excluding restructuring and other items | 1,364 | 3,871 | 9,979 | 14,178 |
| United States | ||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations, excluding restructuring and other items | 13,813 | 8,129 | 36,423 | 30,576 |
| Rest of World | ||||
| Segment Reporting Information [Line Items] | ||||
| Income from operations, excluding restructuring and other items | $ 1,181 | $ 2,773 | $ 6,110 | $ 7,817 |
| X | ||||||||||
- Definition Operating Income Loss Before Restructuring Charges No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution of Property, Plant and Equipment, Net, by Geographical Area (Detail) - USD ($) $ in Thousands |
Sep. 30, 2016 |
Dec. 31, 2015 |
|||
|---|---|---|---|---|---|
| Segment Reporting Information [Line Items] | |||||
| Property, plant and equipment, net | $ 151,375 | $ 150,218 | [1] | ||
| Ireland | |||||
| Segment Reporting Information [Line Items] | |||||
| Property, plant and equipment, net | 106,945 | 101,736 | |||
| Rest Of Europe | |||||
| Segment Reporting Information [Line Items] | |||||
| Property, plant and equipment, net | 6,829 | 7,334 | |||
| United States | |||||
| Segment Reporting Information [Line Items] | |||||
| Property, plant and equipment, net | 31,185 | 34,520 | |||
| Rest of World | |||||
| Segment Reporting Information [Line Items] | |||||
| Property, plant and equipment, net | $ 6,416 | $ 6,628 | |||
| |||||
| X | ||||||||||
- Definition Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution of Depreciation and Amortization by Geographical Area (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
|
| Segment Reporting Information [Line Items] | ||||
| Depreciation and amortization | $ 14,543 | $ 14,366 | $ 44,120 | $ 42,535 |
| Ireland | ||||
| Segment Reporting Information [Line Items] | ||||
| Depreciation and amortization | 6,588 | 5,144 | 19,146 | 14,972 |
| Rest Of Europe | ||||
| Segment Reporting Information [Line Items] | ||||
| Depreciation and amortization | 1,730 | 2,003 | 5,265 | 6,217 |
| United States | ||||
| Segment Reporting Information [Line Items] | ||||
| Depreciation and amortization | 5,368 | 6,277 | 17,154 | 18,412 |
| Rest of World | ||||
| Segment Reporting Information [Line Items] | ||||
| Depreciation and amortization | $ 857 | $ 942 | $ 2,555 | $ 2,934 |
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
Distribution of Total Assets by Geographical Area (Detail) - USD ($) $ in Thousands |
Sep. 30, 2016 |
Dec. 31, 2015 |
[1] | ||
|---|---|---|---|---|---|
| Segment Reporting Information [Line Items] | |||||
| Assets | $ 1,900,478 | $ 1,717,209 | |||
| Ireland | |||||
| Segment Reporting Information [Line Items] | |||||
| Assets | 822,071 | 663,060 | |||
| Rest Of Europe | |||||
| Segment Reporting Information [Line Items] | |||||
| Assets | 352,394 | 343,733 | |||
| United States | |||||
| Segment Reporting Information [Line Items] | |||||
| Assets | 658,016 | 641,769 | |||
| Rest of World | |||||
| Segment Reporting Information [Line Items] | |||||
| Assets | $ 67,997 | $ 68,647 | |||
| |||||
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|